Clinical Research

The retina specialists of Southeastern Retina Associates place a high priority on our commitment to the advancement of medical research. Our physicians continue to be in the forefront with their clinical research participation and in the development of major innovations in retina care.

Southeastern Retina Associates is proud of its participation in research studies demonstrating the highest professional standards and exemplary clinical practice. SERA physicians have been leading clinical trials for more than 15 years! Almost 500 SERA patients have taken part in the research trials. Patient participation in trials is voluntary, and has allowed the latest treatments to become available to all patients who need treatment for advanced eye diseases.

Southeastern Retina participates in several clinical trials that are investigating new forms of treatment for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions.

Below, are descriptions of clinical trials in which we are currently participating or have recently participated at Southeastern Retina Associates’ three East Tennessee main locations. More information on clinical trials is available at clinicaltrials.gov.

 Current Clinical Trials

= currently enrolling = active or ongoing, but not enrolling

Age-Related Macular Degeneration (AMD)

Title

Description

Knoxville

Tri-Cities

Chattanooga

Stairway

Simultaneous Blockade of Angiopoietin-2 And VEGF-A with The Bispecific Antibody RO6867461 (RG7716) For Extended Durability in The Treatment of Neovascular Age-Related Macular Degeneration. Sponsored by Genentech.

SPECTRI

A Phase III randomized, masked, sham controlled study to assess Lampalizumab administered to patients with Geographic Atrophy secondary to Age-Related Macular Degeneration. Sponsored by Genentech.

AVENUE

This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of RG7716 in participants with subfoveal CNV secondary to AMD. Sponsored by Roche.

ATLAS

Optical coherence tomography guided treat and extend therapy for neovascular age-related macular degeneration using aflibercept. Sponsored by Wills Eye Institute.

CAPELLA

Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration. Sponsored by Regeneron.

EXPOSURE

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants with Geographic Atrophy. Sponsored by Genentech.

ONYX

Anti-angiopoeitin 2 Plus Anti-Vascular Endothelial Growth Factor as a Therapy for Neovascular Age Related Macular Degeneration: Evaluation of a Fixed Combination Intravitreal Injection. Sponsored by Regeneron.

MAKO

OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Sponsored by Ohr.

OLEi

A multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies.

Diabetic Retinopathy (DR) Studies

Trials Sponsored by Diabetic Retinopathy Clinical Research network (DRCR.net)

The Diabetic Retinopathy Clinical Research Network facilitates multi-center clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. DRCR studies examine the use of laser treatment and injections. Several protocols are available. The studies are funded by the National Eye Institute, a part of the federal government National Institutes of Health.

Dr. Howard Cummings does an injection on one of SERA’s clinical patients.
STU_0036

 DRCR.net Diabetic Retinopathy Studies

Title

Description

Knoxville

Tri-Cities

Chattanooga

Protocol AA

Peripheral Diabetic Retinopathy (DR) – Lesions on Ultra wide-Field Fundus Images and risk of DR worsening over time.

Protocol AB

Intravitreous anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy

Gene

Blood sample collection and submission to the DRCR Genetic Repository (open only to patients who are currently enrolled in an applicable DRCR study).

Protocol S

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Protocol U

Short-term evaluation of combination Corticosteroid + Anti-VEGF treatment for persistent Central Diabetic Macular Edema.

Protocol V

Treatment for Central Diabetic Macular Edema in Eyes with “Very Good Vision.”

Protocol W

Intravitreous Anti-VEGF Treatment for Prevention of Vision-Threatening Diabetic Retinopathy in Eyes at High Risk.

 

 Diabetic Retinopathy | Diabetic Macular Edema

Title

Description

Knoxville

Tri-Cities

Chattanooga

PALADIN

Phase 4 IOP Signals Associated with ILUVIEN  (Fluocinolone Acetonide Intravitreal Implant 0.19 MG). Indication: Diabetic Macular Edema. Sponsored by Alimera Sciences.

PANORAMA

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy. Sponsored by Regeneron.

Vein Occlusion Studies

 Retinal Vein Occlusion

Title

Description

Knoxville

Tri-Cities

Chattanooga

SCORE2

Study of Comparative Treatments for Retinal Vein Occlusion 2. Sponsored by the National Eye Institute.

To ask about trials currently enrolling and the requirements to take part, patients or referring physicians may call any of SERA’s Clinical Trials Coordinators listed below.

Knoxville
Kristina Oliver or Steve Morris
865.588.0811

Chattanooga
Steve McBee  423.756.1002

Tri-Cities
Amber Anderson 423.578.4364